Iaza Pharma Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-10-2024
- Paid Up Capital ₹ 5.00 M
as on 24-10-2024
- Company Age 12 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 19.52 Cr
as on 24-10-2024
- Revenue -95.54%
(FY 2023)
- Profit -107.90%
(FY 2023)
- Ebitda 7.91%
(FY 2023)
- Net Worth -86.27%
(FY 2023)
- Total Assets -21.12%
(FY 2023)
About Iaza Pharma
The Corporate was formerly known as Mediquip Export House Private Limited. The Company is engaged in the Consumer Goods Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹19.52 Cr.
Kifayat Farooqui, Asadullah Farooque, and Ateek Farooqui serve as directors at the Company.
- CIN/LLPIN
U74110MH2012PTC232737
- Company No.
232737
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Jun 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Iaza Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kifayat Farooqui  | Additional Director | 20-Apr-2024 | Current |
| Asadullah Farooque | Director | 02-Jan-2016 | Current |
| Ateek Farooqui | Director | 09-Mar-2018 | Current |
Financial Performance of Iaza Pharma.
Iaza Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 95.54% decrease. The company also saw a substantial fall in profitability, with a 107.9% decrease in profit. The company's net worth observed a substantial decline by a decrease of 86.27%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iaza Pharma?
In 2023, Iaza Pharma had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Bharat Co-Operative Bank(Mumbai) Ltd Creation Date: 29 Jan 2024 | ₹2.50 M | Open |
The Bharat Co-Operative Bank(Mumbai) Ltd Creation Date: 23 Nov 2023 | ₹11.52 Cr | Open |
Others Creation Date: 08 Feb 2021 | ₹3.00 Cr | Open |
How Many Employees Work at Iaza Pharma?
Unlock and access historical data on people associated with Iaza Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iaza Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iaza Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
